



Medicine Supply Notification

MSN/2026/046

Lacidipine 2mg and 4mg tablets

Tier 2 – medium impact*

Date of issue: 06/10/2026

Link: [Medicines Supply Tool](#)

Summary

- Lacidipine 2mg and 4mg tablets are out of stock until early November 2026.
- Lercanidipine 10mg and 20mg tablets remain available and can support increased demand.
- Amlodipine 2.5mg, 5mg, and 10mg tablets remain available and can support increased demand.
- Felodipine 2.5mg, 5mg, and 10mg modified release (MR) tablets remain available and can support increased demand.
- Nifedipine MR tablets remain available but cannot support an uplift in demand.

Actions Required

Prescribers should not initiate new patients on lacidipine 2mg or 4mg tablets until the shortage has resolved. Where patients have insufficient supply to last until the resupply date, prescribers should review treatment history and consider prescribing:

- lercanidipine tablets, particularly in those who have experienced peripheral oedema on other dihydropyridine calcium-channel blockers (CCBs); or
- another CCB, if appropriate, if above option not suitable.

They should take into account usual licensed dose range (see supporting information), and relevant contraindications, and interactions as outlined in the SmPC, ensuring the patient:

- is not intolerant to any of the excipients;
- is counselled on the change in product and any changes to the dosing regimen;
- has blood pressure monitored approximately four weeks following the switch and after any subsequent dose titrations (if necessary); and
- is advised to report any adverse effects.

*Classification of Tiers can be found at the following link:

<https://www.england.nhs.uk/publication/a-guide-to-managing-medicines-supply-and-shortages/>

Supporting information

Clinical Information

Lacidipine is indicated for the treatment of hypertension, either alone or in combination with other antihypertensive agents.

Amongst the dihydropyridine class of CCBs, lacidipine and lercanidipine are associated with a lower incidence of peripheral oedema compared to amlodipine and nifedipine.

For further information, SPS has produced a [webpage](#) on managing peripheral oedema caused by CCBs.

Dosing

There are no direct dose conversion data. Table adapted from CKS summarises *usual* starting, maintenance, and maximum doses of dihydropyridine calcium-channel blockers for hypertension.

Calcium-channel blocker	Usual starting doses	Usual maintenance dose	Maximum dose
Lacidipine	2 mg once a day	2 to 6 mg once a day	6 mg once a day
Lercanidipine	10 mg once a day	10 to 20 mg once a day	20 mg once a day
Felodipine*	5 mg once a day	5 to 10 mg once a day	20 mg once a day
Amlodipine	5 mg once a day	5 to 10 mg once a day	10 mg once a day

*For dose titration purposes, a 2.5mg tablet is available, if required.

Links to further information

[BNF: Lacidipine](#)

[SmPC: Lacidipine](#)

[SmPC: Lercanidipine](#)

[SmPC: Amlodipine](#)

[SmPC: Felodipine](#)

[Specialist Pharmacy Service: Managing peripheral oedema caused by calcium channel blockers](#)

[NICE CKS: Hypertension Prescribing information: Calcium-channel blockers](#)

Enquiries

If you have any queries, please contact DHSCmedicinesupplyteam@dhsc.gov.uk.